Targeting IL-17A may Modify Risk Factors for Psoriatic Arthritis in Patients with Psoriasis - Video
Overview
Overview
In this short video, Dr. Paolo Gisondi, MD, Associate Professor of Dermatology and Venereology at the University of Verona, Italy, discusses the increased risk of progression from psoriasis to psoriatic arthritis and highlights how treatment with Ixekizumab may modify these key risk factors.
Several factors can drive the transition from psoriasis to psoriatic arthritis, including long-standing or severe skin involvement, scalp or nail psoriasis, and the presence of arthralgia or subclinical enthesopathy.1,2,3,4,5 These features significantly elevate the likelihood of disease progression. However, treatment with biologics has the potential to modify these risk factors and slow or prevent progression. 1-12
Real-world data show that Ixekizumab provides complete skin clearance—including skin, scalp, and nail involvement—in both the short and long term, closely aligning with clinical trial outcomes. Ixekizumab is also approved for the treatment of psoriatic arthritis, and real-world evidence demonstrates its effectiveness in improving both joint and skin manifestations at 12 months. 1-12
References: References: 1. Errichetti E, Zabotti A. Dermatol Ther (Heidelb). 2024;14(1):1-3. 2. Zabotti A, et al. Ann Rheum Dis. 2023;82(9):1162-1170. 3. Wilson FC, et al. Arthritis Rheum. 2009;61(2):233-239. 4. de Vlam K, et al. Acta Derm Venereol. 2014;94(6):627-634. 5. Zabotti A, et al. RMD Open. 2024;10(2):e004314. 6. Gisondi P, et al. Ann Rheum Dis. 2022;81(1):68-73. 7. Pinter A, et al. J Eur Acad Dermatol Venereol. 2022;36(11):2087-2100 (+suppl). 8. Pinter A, et al. Dermatol Ther (Heidelb). 2025 (+suppl). 9. Piaserico S, et al. Front Med (Lausanne). 2023;10:1185523 (+suppl). 10. Riedl E, et al. Dermatol Ther (Heidelb). 2024;14(5):1327-1335 (+suppl). 11. Egeberg A, et al. J Dermatolog Treat. 2023;34(1):2263108. 12. Sewerin P, et al. Presented at EULAR. Barcelona, Spain; 11-14 June 2025.
PP-IX-IN-1005 | 09/12/2025
Eli Lilly and Company (India) Private Limited
For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001, India Ph.: +91-124-4753000/01 | www.lilly.com/in
For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com | For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.
This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.
© 2025 Eli Lilly and Company
